Atypical mutation of epidermal growth factor receptor in resected stage I non-small-cell lung cancers.

This article discusses the atypical mutations of the epidermal growth factor receptor (EGFR) in resected stage I non-small-cell lung cancers (NSCLC). The study found that patients with atypical EGFR mutations had similar disease-free survival (DFS) compared to those with typical EGFR mutations. However, patients with the L861Q mutation had the poorest DFS among those with atypical mutations. The study also explored the differences in DFS between patients with exon 20 insertion mutation and major atypical mutation, suggesting that segmentectomy may not be the best option for patients with major atypical EGFR mutations and solid nodules of less than 2 cm. The article highlights the importance of EGFR testing in personalized care and raises new questions for future studies. [Extracted from the article]

Copyright of European Journal of Cardio-Thoracic Surgery is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)